Aminoalkylphenoxy derivatives

ABSTRACT

Substituted aminoalkylphenoxy derivatives represented by the general formula of: ##STR1## wherein the substituting group Z is either one of the following groups of: ##STR2## These derivatives exert antagonism against Histamine H 2  -receptors and hence are efficacious for the treatments of digestive ulcers.

BACKGROUND OF THE INVENTION

1. Field of the Invention

The present invention relates to aminoalkylphenoxy derivatives, and moreparticularly to aminoalkylphenoxy derivatives and medically acceptablesalts, hydrates and solvates thereof which exert antagonism to histamineH₂ -receptors and thus have utility in medical treatment of digestiveulcers.

2. Description of the Prior Art

It has hitherto been well-known in the art that gastric acid secretioncan be controlled by blocking the histamine H₂ -receptors from thehistamine action and that gastric secretion in an animal or a humanbeing can be suppressed by the use of a substance having an antagonismto the histamine H₂ -receptors. (In this connection, reference should bemade to R. W. Brimblecombe et al., J. Int. Med. Res., 3, 86, 1975.)

Amongst the known histamine H₂ -receptor antagonists, particularlywell-known is Cimetidine which has been presented in the market as thefirst commercially available medicine for treating digestive ulcers.

Considerable research has been made to find substances having antagonismto histamine H₂ -receptors which are superior to that of Cimetidine, anda variety of heterocyclic compounds were synthesized and the antagonismto histamine H₂ -receptor thereof were investigated. Japanese PatentLaid-Open Publication Nos. 165348/1982 and 7177/1984 will be referred toas pertinent references in this connection, and the contents thereofwill be incorporated herein as parts of the specification.

SUMMARY OF THE INVENTION

The object of this invention is to provide novel substitutedaminoalkylphenoxy derivatives which exert superior antagonism tohistamine H₂ -receptors to suppress gastric secretion of animalsappreciably and which also provide shielding functions to protect themucous membrane and to promote the secretion of mucus.

The compounds provided by the present invention are aminoalkylphenoxyderivatives represented by the general formula of: ##STR3## wherein R¹and R² are individually hydrogen atoms or lower alkyl groups having 1 to4 carbon atoms, or R¹ and R² form, together with the bonded nitrogenatom, a four to eight member heterocyclic ring which may have a furthersubstiting group or groups; A is a straight-chain or branched-chainalkylene group having 1 to 4 carbon atoms, and Z is either one of thefollowing groups: ##STR4## wherein R³, R⁴, R⁵, R⁶, R⁷, R⁸, R⁹, R¹⁰, R¹¹,and R¹² are individually hydrogen atoms or alkyl, alkenyl, alkynyl,aralkyl or hetrocyclic aryl alkyl groups; or a four to eight memberheterocyclic group is formed respectively by R³ and R⁴, R⁵ and R⁶, R⁷and R⁸, R⁹ and R¹⁰, R¹¹ and R¹², together with the correspondingnitrogen atoms bonded therewith; and p indicates 0 or 1.

DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS

The present invention will now be described in detail with reference topreferred embodiments thereof.

Initially, examples of the lower alkyl groups having 1 to 4 carbon atomswhich are included as either one or both of the groups R¹ and R² aremethyl, ethyl, propyl, isopropyl, n-butyl, s-butyl and t-butyl groups.

Examples of the hetrocyclic groups formed by the combination of thegroups R¹ and R² together with the nitrogen atom bonded therewith areazetidino-, pyrrolidino-, piperidino- and perhydroazepino- groups. Theseheterocyclic rings may include further substituent groups, such ashydroxyl, methoxy, ethoxy and lower alkyl groups having 1 to 6 carbonatoms.

Examples of alkylene groups, identified by A, include methylene,ethylene, propylene and isobutylene.

In the group Z contained in the general formula defined in the claim,the groups R³ to R¹² include, for example, alkyl groups having 1 to 4carbon atoms, such as methyl, ethyl, n-propyl, iso-propyl, n-butyl,sec-butyl and t-butyl; alkenyl groups, such as ethynyl, 2-propynyl,2-butenyl and 3-butenyl; alkynyl groups, such as 2-propargyl; aralkylgroups, such as benzyl; and heterocyclic aryl alkyl groups, such as2-pyridinomethyl, 3-pyridinomethyl, 2-thiophenomethyl, 3thiophenomethyl,2-furanomethyl and 3-furanomethyl.

Preferred heterocyclic groups, which are formed, respectively, by R³ andR⁴, R⁵ and R⁶, R⁷ and R⁸, R⁹ and R¹⁰, R¹¹ and R¹², together with thecorresponding nitrogen atoms bonded therewith, are azetidino-,pyrrolidino- and piperidino-rings.

The compounds of the invention represented by the general formula (1)may be either in the cis or trans geometrical isomer forms.

Illustrative examples of the compounds provided by the invention andrepresented by the general formula (1) are the following compoundsincluding those specifically referred to in the Examples givenhereinafter.

1-amino-2-[4-<3-(1-pyrrolidino-methyl)phenoxy>-cis-2-butenylamino]-1-cyclobuten-3,4-dione;

1-methylamino-2-[4-<3-(1-pyrrolidino-methyl)phenoxy>-cis-2-butenylamino]-1-cyclobuten-3,4-dione;

1-(2-n-propylamino)-2-[4-<3-(1-pyrrolidino-methyl)phenoxy>-cis-2-butenylamino]-1-cyclobuten-3,4-dione;

1-amino-2-[4-<3-(dimethylaminomethyl)phenoxy>-cis-2-butenylamino]-1-cyclobuten-3,4dione;

1-amino-2-[4-<3-(1-piperidinomethyl)phenoxy>-trans-2-butenylamino]-1-cyclobuten-3,4-dione;

1-methylamino-2-[4-<3-(1-piperidinomethyl)phenoxy>-trans-2-butenylamino]-1-cyclobuten-3,4-dione;

1-amino-2-[4-<3-[1-(1-piperidino)ethyl]phenoxy>-cis-2-butenylamino]-1-cyclobuten-3,4-dione;

1-methylamino-2-[4-<3-[1-(1-piperidino)ethyl]phenoxy>-cis-2-butenylamino-1-cyclobuten-3,4-dione;

1-amino-2-[4-<3-(3-hydroxy-1-piperidinylmethyl)phenoxy>-cis-2-butenylamino]-1-cyclobuten-3,4-dione;

1-methylamino-2-[4-<3-(1-perhydroazepinylmethy)phenoxy>-cis-2-butenylamino]-1-cyclobuten-3,4-dione;

1-benzylamino-2-[4-<3-(1-piperidinomethyl)phenoxy>-cis-2-butenylamino]-1-cyclobuten-3,4-dione;

1-(2-pyridylmethylamino)-2-[4-<3-(1-piperidinomthyl)phenoxy>-cis-2-butenylamino]-1-cyclobuten-3,4-dione;

1-(3-pyridylmethylamino)-2-[4-<3-(1-piperidinomethyl)phenoxy>-cis-2-butenylamino]-1cyclobuten-3,4-dione;

1-(2-thiophenomethylamino)-2-[4-<3-(1-piperidinomethyl)phenoxy>-cis-2-butenylamino]-1-cyclobuten-3,4-dione;

1-(3-thiophenomethylamino)-2-[4-<3-(1-piperidinomethy)phenoxy>-cis-2-butenylamino]-1-cyclobuten-3,4-dione;

6-amino-5-[4-<3-(1-piperidinomethyl)phenoxy>-trans-2-butenylamino]-1,2,4-triazin-3-one;

6-methylamino-5-[4-<3-(1-piperidinomethyl)phenoxy>-trans-2-butenylamino]-1,2,4-triazin-3-one;

6-amino-5-[4-<3-(1-pyrrolidinomethyl)phenoxy>-cis-2-butenylamino]-1,2,4-triazin-3one;

6-methylamino-5-[4-<3-(1-pyrrolidinomethyl)phenoxy>-cis-2-butenylamino]-1,2,4-triazin-3one;

6-ethylamino-5-[4-<3-(1-pyrrolidinomethyl)phenoxy>-cis-2-butenylamino]-1,2,4-triazin-3-one;

6amino-5-[4-<3-(3-hydroxy-1-piperidinomethyl)phenoxy>-cis-2-butenylamino]-1,2,4-triazin-3-one;

6-methylamino-5-[4-(3-dimethylaminomethylphenoxy)-cis-2-butenylamino>-1,2,4-triazin-3-one;6-methylamino-5-[4-(3-dimethylaminomethylphenoxy)-trans-2-butenylamino]-1,2,4-triazin-3-one;

6-amino-5-[4-<3-(1-perhydroazepinylmethyl)phenoxy>-cis-2-butenylamine]-1,2,4-triazin-3-one;

6-methylamino-5-[4-<3-(1-perhydroazephnylmethyl)phenoxy>-cis-2-butenylamino]-1,2,4-triazin-3-one;

4-amino-6-[4-<3-(1-piperidinomethyl)phenoxy>-trans-2-butenylamino]-(1H)-pyrimidin-2-one;

4-methylamino-6-[4-<3-(1-piperidinomethyl)phenoxy>-cis-2-butenylamino]-(1H)-pyrimidin-2-one;

3-[4-<3-(1-piperidinomethyl)phenoxy>-trans-2-butenylamino]-4-amino-1,2,5-thiadiazol;

3-84-<3-(1-piperidinomethyl)phenoxy>-trans-2-butenylamino]-4-methylamino-1,2,5-thiadiazol;

3-[4-<3-(1-piyrrolidinomethyl)phenoxy>-cis-2-butenylamino]-4-amino-1,2,5-thiadiazol;

3-[4-<3-(1-pirrolidinomethyl)phenoxy>-cis-2-butenylamino]-4-methylamino-1,2,5-thiadiazol;

3-[4-<3-(dimethylaminomethyl)phenoxy>-cis-2-butenylamino]-4-methylamino-1,2,5-thiadiazol;

3-[4-<3-(1-piperidinomethyl)phenoxy>-trans-2-butenylamino]-4-amino-1,2,5-thiadiazol-1-oxide;

3-[4-<3-(1-piperidinomethyl)phenoxy>-trans-2-butenylamino]-4-methylamino-1,2,5-thiadiazol-1-oxide;

3-[4-<3-(1-piperidinomethyl)phenoxy>-trans-2-butenylamino]-4-propargylamino-1,2,5-thiadiazol-1-oxide;

3-[4-<3-(1pirrolidinomethyl)phenoxy>-cis-2-butenylamino]-4-methylamino-1,2,5-thiadiazol-1-oxide;

3-[4-<3-(dimethylaminomethyl)phenoxy>-cis-2-butenylamino]-4-methylamino-1,2,5-thiadiazol-1-oxide;

3-[4-<3-(1-piperidinomethyl)phenoxy>-cis-2-butenylamino]-4-benzylamino-1,2,5-thiadiazol-1-oxide;

3-[4-<3-(1-piperidinomethyl)phenoxy>-cis-2-butenylamino]-4-(2-pyridinomethylamino)-1,2,5-thiadiazol-1-oxide;

3-[4-<3-1(1-piperidinomethyl)phenoxy>-cis-2-butenylamino]-4-(3-pyridinomethylamino)-1,2,5-thiadiazol-1-oxide;

3-[4-<3-(1-piperidinomethyl)phenoxy>-cis-2-butenylamino]-4-(2-thiophenomethylamino)-1,2,5-thiadiazol-1-oxide;

3-[4-<3-(1-piperidinomethyl)phenoxy>-cis-2-butenylamino]-4-(3-thiophenomethylamino)-1,2,5-thiadiazol-1-oxide;

2[4-<3-(1-piperidinomethyl)phenoxy>-cis-2-butenylamino]-5-amino-1,3,4-thiadiazol;

2-[4-<3-(1-piperidinomethyl)phenoxy>-cis-2-butenylamino]-5-methylamino-1,3,4-thiadiazol;

2-[4-<3-(1-pyrrolidinomethyl)phenoxy>-cis-2-butenylamino]-5-amino-1,3,4-thiadiazol;

2-[4-<3-(1-pyrrolidinomethyl)phenoxy>-cis-2-butenylamino]-5-methylamino-1,3,4-thiadiazol;

2-[4-<3-(dimethylaminomethyl)phenoxy>-cis-2-butenylamino]-5-amino-1,3,4-thiadiazol;

2-[4-<3-(dimethylaminomethyl)phenoxy>-cis-2-butenylamino]-5-methylamino-1,3,4-thiadiazol;

2-[4-<3-(1-piperidinomethyl)phenoxy>-trans-2-butenylamino]-5-amino-1,3,4-thiadiazol;

2-[4-<3-(1-pyieridinomethyl)phenoxy>-trans-2-butenylamino]-5-methylamino-1,3,4-thiadiazol;

2-[4-<3-(1-pyrrolidinomethyl)phenoxy>-trans-2-butenylamino]-5-ethylamino-1,3,4-thiadiazol;and

2-[4-<3-(1-pyrrolidinomethyl)phenoxy>-trans-2-butenylamino]-5-n-propylamino-1,3,4-thiadiazol.

The compounds of the invention represented by the general formula (1)and the salts thereof may be prepared, depending on the substituents Zincluded therein, through the following differenct processes.

(A) Compounds wherein Z is ##STR5## First Step: ##STR6## Second Step:##STR7##

In the reaction equations set forth above, R¹, R², R³ and R⁴ are thegroups as described hereinbefore and defined in the claims; R²⁰ is alower alkyl, preferably methyl; and E is --O-- or --S--, preferably--O--.

The first and second steps may be carried out separately, but it ispreferable that both stpes be carried out as continuous sequence. It ispreferred that both of the starting materials are used in the equivalentmolar ratio in the first step, whereas in the second step it ispreferred that the amine ##STR8## is used in an excess amount, forexample, in an amount of two to five times the moles of the resultantproduact of the first step.

Both steps may be carried out without using a solvent or may be carriedout in a solvent, and an inert organic solvent, such as methanol,ethanol, propanol, acetonitrile or chloroform, may be used in the lattercase. The reaction temperature ranges generally from 0° C. to theboiling point of the used solvent, the boiling points of the usablesolvents ranging generally from 50° C. to 150° C., and the preferabletemperature range is from room temperature to 80° C. The time requiredfor the completion of reaction is varied depending on the reactiontemperature, and both reactions may be completed within 30 minutes to 24hours.

The following known compounds may be used as the exemplary startingmaterials in the first step.

For instance, the compounds represented by the formula: ##STR9## may beprepared by the process disclosed in the specification of JapanesePatent Laid-Open Publication No. 165348/1982; and the derivativesthereof may be prepared through similar processes.

On the other hand, one of the compounds represented by the formula:##STR10## i.e. the compound ##STR11## may be prepared by the processdisclosed by Sidney Cohenet et al, in J. Am. Chem. Soc., 88 (7), 1533(1966).

(B) Compounds wherein Z is ##STR12## wherein R¹, R², R⁵, R⁶ and A arethe same as defined above; and B is R³⁰ S-- (R³⁰ being an alkyl group,preferably methyl) or a halogen (chlorine, bromine or iodine) atom.

The reaction set forth above may proceed at 50° C. to 150° C. in aninert organic solvent or without using any solvent. Examples of theinert solvents include alcohols, preferably methanol, ethanol andpropanol, and the reaction may proceed preferably under reflux of such asolvent.

The compounds represented by the formula: ##STR13## may be prepared bythe process reported by C. C. Tzeng et al, in J. Org. Chem., 26, 1118(1961), or by a modified process thereof which should be obvious tothose having ordinary skill in the art.

(C) Compounds wherein Z is ##STR14## wherein R¹, R², R⁷ and R⁸ are thesame as defined above; and D is a halogen (chlorine, bromine and iodine)atom or a lower alkylthio group.

The compounds represented by the following formula: ##STR15## forexample hydrochloride of 6-amino-4-chloro-2(1H)-pyrimidone, may beprepared by the process reported by Wolfgang Pfleiderane et al, in Ann.,657, 149 (1962). The reaction may proceed in a solvent or without usingany solvent. Usable solvents include, for example, methanol, ethanol,water, DMF and DMSO. The reaction may proceed at 50° C. to 150° C. for 5minutes to 24 hours under agitation.

(D) Compounds wherein Z is ##STR16## First Step: ##STR17## Second Step:##STR18## wherein R¹, R², R⁹, R¹⁰ and p are the same as defined above;R⁴⁰ is a lower alkyl, preferably methyl; and F indicates --S-- or --O--.

The compounds used in the first step and represented by the formula:##STR19## are known compounds, and 3,4-dimethoxy-1,2,5-thiaziazol##STR20##

(p=0) may be prepared by a process reported by A. P. Komin et al. in J.Org. Chem., 40, 2749 (1975) or a modified process thereof and3,4-dimethoxy-1,2,5-thiaziazol-1-oxide ##STR21##

(p=1) may be prepared by a process described in Japanese PatentLaid-Open Publication No. 40675/1981 or by a modified process thereof.

The first step set forth hereinabove may be carried out, for example, byreacting one mole of a derivative of4-<(3-dialkylaminoalkyl)phenoxymethyl>-2-butenylamine with one to threemoles of 3,4-dimethoxy-1,2,5-thiadiazol or3,4-dimethoxy-1,2,5-thiadiazol-1-oxide in the absence of a solvent or inan inert organic solvent (a lower alcohol, preferably methanol, ethanolor propanol) at a reaction temperature of from -10° C. to 100° C.,preferably from 0° C. to 30° C. under agitation. The reaction iscompleted within 30 minutes to 24 hours, and the end of the reaction maybe checked by means of T.L.C. thin layer chromatography.

The reaction of the first step may be continued to the reaction of thesecond step in a continuous operation sequence. Alternatively, thesecond step operation may be carried out after refining the resultantproduct of the first step, for example, by means of columnchromatography.

The second step operation is carried out by dissolving the resultantproduct of the first step in an inert organic solvent followed byaddition of an amine compound represented by the formula of: ##STR22## 2to 10 moles of amine, relative to one mole of the resultant produce ofthe first step, are used; and the second step is carried out generallyat a reaction temperature of from -10° C. to 100° C., preferably from 0°C. to 30° C. The reaction is completed within 30 minutes to 12 hours.When R⁹ and R¹⁰ are bydrogen atoms, the resultant product of the secondstep, for instance,3-[4-(3-dialkylaminoalkylphenoxy)-2-butenylamino]-4-amino-1,2,5-thiadiazol-1-oxide:##STR23## may be treated with a mineral acid to obtainN-[4-(3-dialkylaminoalkylphenoxy)-2-butenyl]ethanediimidamide or amineral acid salt thereof. Thereafter, the resultant product may bereacted with 1 to 10 moles of sulfur monochloride orN,N'-thiobisphthalimide, relative to one mole of the resultant productto convert into3-[4-(3-dialkyl-aminoalkylphenoxy)-2-butenylamino]-4-amino-1,2,5-thiadiazol.

Other than the aforementioned process, the same product can be preparedthrough the following sequential reactions: ##STR24##

(E) Compounds wherein Z is a group represented by: ##STR25##

Such a compound can be prepared through the following reactions:##STR26##

Alternatively, such a compound may be prepared by the process includingthe following first and second steps:

First Step: ##STR27## Second Step: ##STR28## wherein R¹, R², A, R¹¹, R¹²and X are the same as defined above.

Although the latter process has a larger number of steps, it isgenerally favoured because of decreased by-products and increased yield.

As further modified processes for the preparation of the compoundsrepresented by the general formula (I), it may be mentioned thatutilizing the following reaction: ##STR29## wherein R¹, R², A, and Z arethe same as defined above; M is an alkali metal, preferably sodium orpotassium; and X is a halogen atom, such as chlorine, bromine or iodine;and that utilizing the following reaction: ##STR30## wherein R¹, R², A,X, M and Z are the same as defined above.

Pharmaceutical Efficacies of the Compounds of the Invention

Some compounds of this invention were tested and compared withCimetidine which has been widely used for clinic applications as amedicine for digestive ulcers as having an antagonistic function on thehistamine H₂ -receptor.

(A) Inhibition Effect on Gastric Acid Secretion Induced by Histamine inits Pylorus Ligated Rat

The test was conducted by an improved method of that reported byWatanabe et al., in "Pharmacometrics", Vol. 3, No. (1), pages 7 to 14(1969).

A male Wistar rat having a body weight of about 160 g and which had notfed for 24 hours was anesthetized by an intraperitonea dose of 1.2 g/kgof uretane. After ligating of pylorus and esophagus, the gaster anteriorwas incised and fitted with a double polyethylene cannula. The wall ofthe stomach was rinsed with 5 ml of saline at 30 minute intervals, andthe quantities of gastric acid contained in each rinsing solution weremeasured by titration.

The basal acid secretion was initially measured three times, and then0.2 mg/kg or 0.5 mg/kg of each of the compounds of this invention wasadministered subcutaneously and 3 mg/kg of histamine was administeredsubcutaneously after the lapse of an additional 30 minutes.

The quantity of gastric acid secreated after the operation was measuredcontinuously for 3 hours. Within that measurement interval, three timepoints at which the increase in acid secretion reached a maximum levelwere selected, and the average quantity of gastric acid secreted atthose time points was taken as the increase in acid secretion, which wascompared with the increase in acid secretion of the control group tocalculate the percent inhibition for secretion of gastric acid. ##EQU1##(The result was shown as the average value of five runs.)

Each of the compounds having strong inhibition effects on the secretionof gastric acid was administered to each rat intraduodenally 30 minutesbefore the subcutaneous injection of histamine to find the amount toadminister for suppressing gastric acid secretion by 50% (ED₅₀). Theresults are shown in table 1.

(B) Determination of Inhibitory Effect on Histamine H₂ -Receptor inisolated Guinea Pig Atria

A male Hartley guinea pig having a body weight of about 400 g was killedby cervical dislocation, and the artrium thereof was isolated and wassuspended in an organ bath containing 50 ml of a modified Ringersolution and subjected to a tension of 1 g. The number of heart beatsunder such condition was recorded using a polygraph.

Initially, from 1×10⁻⁷ mol to 3×10⁻⁴ mol of histamine was allowed to actaccumulatively to depict the curve of the dosage-reaction relationship.Likewise, the curve of the dosage of histamine-reaction relationship wasdepicted in the presence of 5×10⁻⁷ mol to 1×10⁻⁶ mol of the test samplewhich was injected 3 minutes before. The negative logarithm (pA₂) of themolar concentration of the test sample required for moving the curveobtained by single administration of histamine parallel to the rightside by a two-times concentration was calculated.

The results are shown in Table 1.

(C) Acute Toxicity Test

Male ddy mice each having a body weight of about 22 g and which had noteaten for 8 hours were orally dosed with the test samples, and thegeneral symptoms and fatalities were observed from the time immediatelyfollowing the administration to 14 days after the administration.

The median lethal dose (LD₅₀) was calculated in accordance with theLitchfield and Wilcoxon Method.

The results are shown in Table 3.

                  TABLE 1                                                         ______________________________________                                        Inhibitory Effect on Gastric Acid Secretion by Histamine in                   Pylorus ligated rat and Determination of Inhibitory Effect on                 Histamine H.sub.2 -Receptor in isolated Guinea Pig Atria                                 Secretion of                                                                  Gastric   Antagonistic Action                                                 Acid in Rat                                                                             against Histamine                                                             Inhi-   H.sub.2 -Receptor (pA.sub.2)                                  Dosage  bition  Determined by Using                                           mg/kg   Rate    Atrium isolated                                  Sample       (SC)    (%)     from Guinea Pig                                  ______________________________________                                        Compound of Ex. 2                                                                          0.5     98**    7.20                                             Compound of Ex. 3                                                                          0.5     79**    6.51                                             Compound of Ex. 4                                                                          0.2     66      6.11                                             Compound of Ex. 6                                                                          0.2     25      6.75                                             Compound of Ex. 7                                                                          0.2     28      6.29                                             Compound of Ex. 8                                                                          0.2     88*     6.82                                             Compound of Ex. 9                                                                          0.5     96**    6.73                                             Compound of Ex. 10                                                                         0.5     103**   6.66                                             Compound of Ex. 11                                                                         0.2     88**    6.18                                             Compound of Ex. 12                                                                         0.2     44**    5.82                                             Compound of Ex. 13                                                                         0.5     91**    7.08                                             Compound of Ex. 14                                                                         0.2     -9      5.15                                             Compound of Ex. 15                                                                         0.5     98**    6.36                                             Compound of Ex. 16                                                                         0.5     98**    5.62                                             Compound of Ex. 17                                                                         0.2     86*     7.01                                             Compound of Ex. 19                                                                         0.2     82*     5.62                                             Compound of Ex. 20                                                                         0.2     88**    6.41                                             Compound of Ex. 21                                                                         0.2     99**    6.64                                             Compound of Ex. 22                                                                         0.2     88**    6.50                                             Compound of Ex. 25                                                                         0.2     77**    6.69                                             Compound of Ex. 26                                                                         0.2     45*     5.02                                             Compound of Ex. 27                                                                         0.2     87*     6.31                                             Compound of Ex. 28                                                                         0.2     75      5.33                                             Compound of Ex. 29                                                                         0.2     36      6.50                                             Compound of Ex. 30                                                                         0.2     17      6.26                                             Control (Cimetidine)                                                                       0.5     41**    6.45                                             ______________________________________                                         Note:                                                                         Values affixed with * or ** indicates that significant differences as of      < 0.05 or p < 0.01 were observed as compared to the control group.       

                  TABLE 2                                                         ______________________________________                                        Inhibitory Effect of intraduodenally administered                             compounds of the invention on Gastric Acid Secretion                          induced by Histamine in Rat                                                           Median                                                                        effective dose (ED.sub.50)                                                                    Efficacy Ratio                                                induced Gastric Acid Section                                                                  relative to                                                              (95% Reliability                                                                           Cimetidine                                    Sample    (mg/kg)  Limit)       (Cimetidine = 1)                              ______________________________________                                        Compound of                                                                             0.046    (0.009˜0.25)                                                                         156.5                                         Ex. 2                                                                         Compound of                                                                             0.036    (0.005˜0.25)                                                                         200.0                                         Ex. 3                                                                         Compound of                                                                             0.070    (0.14˜3.85)                                                                          10.3                                          Ex. 8                                                                         Compound of                                                                             8.0      (not obtainable)                                                                           0.9                                           Ex. 10                                                                        Compound of                                                                             0.44     (0.07˜2.62)                                                                          16.4                                          Ex. 11                                                                        Compound of                                                                             0.52     (not obtainable)                                                                           13.8                                          Ex. 13                                                                        Compound of                                                                             0.066    (0.002˜1.84)                                                                         109.1                                         Ex. 15                                                                        Compound of                                                                             0.04     (0.005˜0.34)                                                                         180.0                                         Ex. 16                                                                        Compound of                                                                             0.82     (0.24˜2.83)                                                                          8.8                                           Ex. 17                                                                        Compound of                                                                             0.88     (not obtainable)                                                                           8.2                                           Ex. 19                                                                        Compound of                                                                             0.58     (0.34˜0.99)                                                                          9.0                                           Ex. 20                                                                        Compound of                                                                             2.0      (0.39˜10.2)                                                                          3.6                                           Ex. 21                                                                        Compound of                                                                             0.62     (0.18˜2.11)                                                                          11.6                                          Ex. 22                                                                        Compound of                                                                             0.45     (0.16˜1.26)                                                                          16.0                                          Ex. 27                                                                        Compound of                                                                             0.62     (0.18˜1.54)                                                                          11.6                                          Ex. 28                                                                        Reference Ex. 1                                                                         0.2      (0.04˜0.93)                                                                          36.0                                          Reference Ex. 2                                                                         0.44     (0.05˜3.96)                                                                          16.4                                          Control   7.2      (1.8˜28.1)                                                                           1                                             (Cimetidine)                                                                  ______________________________________                                    

                  TABLE 3                                                         ______________________________________                                        Acute Toxicity Test on Mice Dosed Orally                                                     Median lethal dose (LD.sub.50)                                 Sample         mg/kg P.O.                                                     ______________________________________                                        Compound of Ex. 2                                                                            >1500                                                          Compound of Ex. 3                                                                            >1500                                                          Compound of Ex. 9                                                                             1200                                                          Compound of Ex. 10                                                                           >1500                                                          Compound of Ex. 13                                                                           >1500                                                          Compound of Ex. 16                                                                           >1500                                                          Control (Cimetidine)                                                                          3300                                                          ______________________________________                                    

As will be clearly seen from Table 1, the inhibitive actions of therespective compounds, prepared by Examples of the invention andadministered subcutaneously on gastric acid secretion induced byhistamine were greater compared to that of Cimetidine. The antagonisticactions against Histamine H₂ -receptor of the compounds of thisinvention were comparable with or superior to that of Cimetidine, whentested using isolated right stria of guinea pigs.

Another characteristic effecr of the compound of this invention that wasascertained is that the inhibitory effect on gastric acid secretion bythe intraduodenal administration, which is similar to oraladministration, was extremely higher. For instance, as shown in Table 2,from the ED₅₀ values of the compounds prepared, respectively, byExamples 2, 3, 15 and 16 were about 157, 200, 110 and 180 times as moreeffective as the ED₅₀ value of Cimetidine. Particularly, the compoundsof this invention, prepared by Examples 15 and 16, showed activity ratioof 110 times and 180 times as high as that of Cimetidine, and theactivities as such were clearly higher than those of the affinitivecompounds prepared by Reference Examples 1 and 2 to show, respectively,36 times and 16 times higher activities. (In this connection, referenceshould be made to Table 2.)

The acute toxicity tests conducted by administering the compounds tomice orally revealed that almost all of the tested compounds had theLD₅₀ values of more than 1500 mg/kg, showing that the toxicities thereofwere low.

Accordingly, it should be appreciated that the compounds of thisinvention have remarkable utility when used as anti-pectic ulcer drugs,since they exhibit powerful inhibitory effects against Histamine H₂-receptor and potent suppression effects on gastric acid secretion andyet are less toxic.

Examples Of The Invention EXAMPLE 1: Preparation of1-methoxy-2-[4-<3-(1-piperidinomethyl)phenoxy>-cis-2-butenylamino]-1-cyclobuten-3,4-dione

One gram (0.00344 mol) of4-<3-(1-piperidinomethyl)phenoxy>-cis-2-butenylamine was dissolved in 25ml of absolute ethanol, and added with 0.55 g (0.00387 mol) of dimethylsqualate (prepared by the process reported by Sidney Cohen et al, in J.Amer. Chem. Soc., Vol. 88, 1533 (1966)) followed by agitation at theroom temperature for 4 hours. The solvent was distilled off after thecompletion of the reaction, and the residue was passed through a silicagel column chromatogram to be purified, followed by elution with a mixedsolution of ethyl acetate/methanol=4/1. As a result, 1.15 g (Yield:81.0%) of the captioned compound was obtained as a light yellow oilyproduct.

IR (neat, cm⁻¹): 2950, 1805, 1718, 1610, 1280, 1120, 1020, 1000, 870,750, 700, 660.

NMR(CDCl₃, ppm): 1.2-1.9(6H, m), 2.1-6(4H, m), 3.35(3H, s), 3.40(2H, s),4.3-4.5(2H, m), 5.5-5.7(2H, m), 6.5-7.3(4H, m), 7.9(1H, b Disappeared byD₂ O treatment).

EXAMPLE 2 Preparation of1-amino-2-[4-<3-(1-piperidinomethyl)phenoxy>-cis-2-butenylamino]-cyclobuten-3,4-dione

1.15 grams (0.0031 mol) of the1-methoxy-2-[4-<3-(1-piperidinomethyl)phenoxy>-cis-2-butenylamine]-1-cyclobuten-3,4-dionewas dissolved in 23 ml of absolute ethanol to obtain a solution throughwhich dry ammonia gas was passed at room temperature for 20 minutes, andthen the solution was agitated at room temperature for additional 2hours. The solvent was distilled off under reduced pressure after thecompletion of the reaction, and the residue was passed through a silicagel column chromatogram to purify the same, followed by elution with amixed solution of ethyl acetate/methanol=4/1. Whereupon, 0.87 g (Yield:78.9%) of the captioned compound was obtained in a colorless crystalform, which had a melting point of 223° to 225° C.

IR(KBr, cm⁻¹): 3340, 3150, 2950, 1815, 1650, 1570, 1540, 1450, 1260,1150, 1040, 780, 700, 600.

NMR(DMSO-d₆, ppm): 1.1-1.8(6H, m), 2.0-2.2(4H, m) 3.35(2H, s),3.9-4.4(3H, m, Disappeared by D₂ O treatment), 4.5-4.7(2H, d),5.5-5.9(2H, m), 6.5-7.2(4H, m), 7.2-7.6(2H, m, Disappeared by D₂ Otreatment).

EXAMPLE 3 Preparation of1-methylamino-2-[4-<3-(1-piperidinomethyl)phenoxy>-cis-2-butenylamino]-cyclobuten-3,4-dione

1.28 (0.00346 mol) of the1-methoxy-2-[4-<3-(1-piperidinomethyl)phenoxy>-cis-2-butenylamino]-1-cyclobuten-3,4-dioneobtained in Example 1 was dissolved in 12.8 ml of methanol, added with10 ml of a 40% methylamine solution in methanol, and agitated at roomtemperature for 2 hours. The solvent was distilled off under reducedpressure after the completion of the reaction, and the residue waspassed through a silica gel column chromatogram to purify the same,followed by elution with a mixed solution of ethyl acetate/methanol=4/1.Whereupon, 1.08 g (Yield: 84.6) of the captioned compound was obtainedin a colorless crystal form, which had a melting point of 214° to 217°C. (decomposed at that temperature).

IR(KBr, cm⁻¹): 3190, 2950, 1805, 1665, 1570, 1400, 1280, 1040, 775, 685,600.

NMR(DMSO-d₆, ppm): 1.1-1.6 (6H, m), 2.0-2.5 (4H, m), 2.95 (3H, s), 3.2(2H, s), 4.0-4.5 (2H, m), 4.35-4.7 (2H, m), 5.4-5.7 (2H, m), 6.5-7.5(4H, m).

EXAMPLE 4 Preparation of1-(2-propagylamino)-2-[4-<3-(1-piperidinomethyl)phenoxy>-cis-2-butenylamino]-1-cyclobuten-3,4-dione##STR31##

Yield: 69.9%

Melting Point: 114° to 119° C.

IR(KBr, cm⁻¹): 3300, 2950, 1620, 1490, 1450, 1340, 1260, 1030.

NMR(CDCl₃, ppm): 1.1-1.6 (6H, m), 2.1-2.7 (4H, m), 3.5 (2H, s), 4.0-4.3(2H, m), 4.3-4.8 (2H, m), 5.4-6.0 (2H, m), 6.5-7.5 (4H, m).

EXAMPLE 5 Preparation of1-methoxy-2-[4-<3-(1-piperidinomethyl)phenoxy>-trans-2-butenylamino]-1-cyclobuten-3,4-dione##STR32##

Light Yellow Oily Product

Yield: 74.0%

IR(neat, cm⁻¹): 3210, 2950, 1810, 1720, 1610, 1380, 1350, 1260, 1160,1040, 800.

NMR(CDCl₃, ppm): 1.2-1.7 (6H, m), 2.1-2.5 (4H, m), 3.4 (2H, s), 3.8-4.2(2H, m), 4.3 (3H, s), 4.3-4.6 (2H, m), 5.7-5.95 (2H, m), 6.5-7.3 (4H,m).

EXAMPLE 6 Preparation of1-amino-2-[4-<3-(1-piperidinomethyl)phenoxy>-trans-2-butenylamino]-1-cyclobuten-3,4-dione##STR33##

Yield: 82%

Melting point: 220° to 227° C.

IR(KBr, cm⁻¹): 3320, 3150, 2950, 1810, 1650, 1570, 1340, 1260, 1150,960, 860, 770, 690.

NMR(DMSO-d₆ /CDCl₃, ppm):

1.2-1.9 (6H, m), 2.1-2.6 (4H, m), 3.35 (2H, s), 4.0-4.3 (2H, m),4.35-4.6 (2H, m), 5.7-6.0 (2H, m), 6.5-7.2 (4H, m), 7.15-7.3 (2H, mDisappeared by D₂ O treatment).

EXAMPLE 7 Preparation of1-methylamino-2-[4-<3-(1-piperidinomethyl)phenoxy>-trans-2-butenylamino]-1-cyclobuten-3,4-dione##STR34##

Yield: 77.2%

Melting point: 216° to 218° C.

IR(KBr, cm⁻¹): 3200, 2950, 1810, 1660, 1570, 1390, 1260, 1150, 1020.

NMR(DMSO-d₆ /CDCl₃, ppm): 1.0-1.7 (6H, m), 1.9-2.6 (4H, m), 3.1 (3H, s),3.3 (2H, s), 3.9-4.3 (2H, m), 4.3-4.6 (2H, m), 5.6-6.0 (2H, m), 6.5-7.3(4H, m), 8.1 (1H, bro., Disappeared by D₂ O treatment).

EXAMPLE 8 Preparation of1-amino-2-[4-<3-(1-pyrrolidinomethyl)phenoxy>-cis-2-butenylamino]-1-cyclobuten-3,4-dione##STR35##

Yield: 68.5%

Melting Point: 212° to 217° C.

IR(KBr, cm⁻¹): 3150, 2970, 2800, 1810, 1650, 1570, 1535, 1330, 1270,1150, 1080, 690.

NMR(DMSO-d₆, ppm): 1.4-1.9 (4H, m), 2.2-2.6 (4H, m) 3.45 (2H, m),3.6-4.0 (2H, bro. Vanished by the treatment with D₂ O), 4.0-4.8 (2H, m),4.45-4.7 (2H, m), 5.5-5.7 (2H, m), 6.5-7.1 (4H, m).

EXAMPLE 9 Preparation of6-amino-5-[4-<3-(1-piperidinomethyl)phenoxy>-cis-2-butenylamino]-1,2,4-triazin-3-one

1.2 g (0.0046 mol) of4-<3-(1-pyperidinomethyl)phenoxy>-cis-2-butenylamine and 0.6 g (0.0046mol) of 6-amino-5-mercapto-1,2,4-triazin-3-one (prepared by the processreported by C. C. Tzeng et al, J. Org. Chem., Vol. 48, 1273 (1983)) wererefluxed in 30 ml of methanol for an hour. The solvent was distilled offafter the completion of the reaction, and the residue was added with asmall quantity of methanol and then cooled. The precipitated crystal wasrecrystallized from ethanol to obtain 1.3 g (Yield: 76.0%) of acolorless cystal. The melting point of the thus obtained crystal was212° to 214° C. at which the crystal was decomposed.

IR(KBr, cm⁻¹): 3250, 2950, 1640, 1460, 1260, 1040.

NMR(DMSO-d₆, ppm): 1.2-1.8 (6H, m), 2.0-2.5 (4H, m), 3.33 (2H, s),3.8-4.3 (2H, m), 4.62 (2H, d), 5.49 (2H, m) 5.3-5.9 (2H, m), 6.5-7.3(4H, m), 7.82 (1H, bro. Disappeared by D₂ O treatment), 11.46 (1H, bro.,Disappeared by D₂ O treatment).

EXAMPLE 10 Preparation of6-methylamino-5-[4-<3-(1-piperidinomethyl)phenoxy>-cis-2-butenylamino]-1,2,4-triazin-3-one##STR36##

Yield: 74%

Melting Point: 73° to 75° C.

IR(KBr, cm⁻¹): 3350, 2950, 1500, 1430, 1280, 1050, 790.

NMR(DMSO-d₆, ppm): 1.1-1.8 (6H, m), 2.1-2.5 (4H, m), 2.69 (3H, d), 3.33(2H, s), 3.8-4.3 (2H, m), 4.60 (2H, d), 5.2-6.1 (2H, m), 5.95 (1H, bro.Disappeaved by D₂ O treatment) 6.4-7.3 (4H, m).

EXAMPLE 11 Preparation of6-amino-5-[4-<3-(1-piperidinomethyl)phenoxy>-trans-2-butenylamino]-1,2,4-triazin-3-one##STR37##

Yield: 45.7%

Melting Point: 215° to 222° C.

IR(KBr, cm⁻¹): 3220, 2940, 1640, 1580, 1470, 1340, 1300, 1255, 1155,1035, 770, 690.

NMR(DMSO-d₆ /CDCl₃, ppm): 1.2-1.8 (6H, m), 1.95-2.55 (4H, m), 3.3 (2H,s), 3.8-4.2 (2H, m), 4.2-4.55 (2H, m), 5.3-6.0 (4H, m), 6.4-7.2 (4H, m)7.7-8.1 (1H, bro, Disappeared by D₂ O treatment).

EXAMPLE 12 Preparation of2-methyl-6-methylamino-5-[4-<3-(1-piperidinomethyl)phenoxy>-trans-2-butenylamino]-1,2,4-triazin-3-one##STR38##

Yield: 52.8%

Melting Point: 139° to 140° C.

IR(KBr, cm⁻¹): 3300, 2940, 1590, 1520, 1440, 1360, 1260, 1160, 1020,965, 860, 800, 770, 700, 600, 550, 480.

NMR(CDCl₃, ppm): 1.25-1.8 (6H, m), 2.15-2.5 (4H, m) 2.8 (3H, s), 3.35(2H, s), 3.5 (3H, s), 3.9-4.2 (2H, m), 4.2-4.5 (2H, m), 5.65-5.95 (2H,m), 6.4-7.25 (4H, m), 8.2-8.75 (1H, bro. Disappeared by D₂ O treatment).

EXAMPLE 13 Preparation of4-amino-6-[4-<3-(1-piperidinomethyl)phenoxy>-cis-2-butenylamino]-(1H)-pyrimidin-2-one

One gram (0.0038 mol) of4-<3-(1-piperidinomethyl)phenoxy>-2-butenylamine and 0.23 g (0.0013 mol)of 6-amino-4-chloro-(1H)-pyrimidin-2-one hydrochloride (prepared by theprocess reported by Wolfgang Pfleiderene et al, Ann., 657, 149 (1962))were refluxed under heating with 1.5 ml of water for 50 minutes. Afterthe completion of the reaction, the precipitated crystal was filteredand dried, and then recrystallized from methanol to obtain 0.38% (Yield:81.3%) of the captioned compound. The thus obtained crystalline producthad a melting point of 225° to 227° C.

IR(KBr, cm⁻¹): 3500, 3170, 2950, 1680, 1650, 1620, 1545, 1525, 1450.

NMR(DMSO-d₆, ppm): 1.2-1.6 (6H, m), 2.1-2.4 (4H, m), 2.3 (2H, s),3.6-4.0 (2H, m), 4.45-4.7 (2H, m), 4.65 (1H, s), 5.45-5.7 (2H, m),6.5-7.1 (8H, m, 4H Disappeaved by D₂ O treatment).

EXAMPLE 14 Preparation of1-methyl-4-amino-6-[4-<4-<3-(1-piperidinomethyl)phenoxy>-trans-2-butenylamino]-(1H)-pyrimidin-2-one##STR39##

Yield: 72.6%

Melting Point: 169° to 175° C.

IR(KBr, cm⁻¹): 3450, 3200, 2940, 2800, 1640, 1620, 1570, 1490, 1365,1270, 1040, 970, 860, 780, 690, 640.

EXAMPLE 15 Preparation of3-amino-4-[4-<3-(1-piperidinomethyl)phenoxy>-cis-2-butenylamino]-1,2,5-thiadiazol-1-oxide

1.3 g (0.005 mol) of4-4-<3-(1-piperidinomethyl)phenoxy>-cis-2-butenylamine was dissolved in25 ml of absolute alcohol and added with 0.81 g (0.005 mol) of3,4-dimethoxy-1,2,5-thiadiazol-1-oxide (prepared by the processdisclosed by Japanese Patent Laid-open publication No. 40675/1981),followed by agitation at room temperature for an hour. Thereafter, dryammonia gas was passed through the solution for 20 minutes, and thesolution was agitated for additional one hour to complete the reaction.

The solvent was distilled off under reduced pressure, and the residuewas passed through a silica gel column chromatogram to purify the same,followed by elution with a mixed solution of ethyl acetate/methanol=4/1,to obtain 1.1 g of the captioned compound in a colorless crystal (Yield:58.7%). The thus obtained product had a melting point of 134° to 137° C.

IR(KBr, cm⁻¹): 3310, 3150, 3050, 2950, 1620, 1260, 1160, 1040, 850, 695,520.

NMR(CDCl₃, ppm): 1.2-1.9 (6H, m), 2.2-2.7 (4H, m), 2.9 (3H, s), 3.5 (2H,s), 3.8-4.2 (2H, m), 4.4-4.7 (2H, m), 5.5-5.8 (2H, m), 6.5-7.3 (4H, m).

EXAMPLE 16 Preparation of3-methylamino-4-[4-<3-(1-piperidinomethyl)phenoxy>-cis-2-butenylamino]-1,2,5-thiadiazol-1-oxide

Generally following to the procedures as described in Example 15, exceptin that the reaction with ammonia gas was replaced by the reaction with2 ml of a 40% methylamine solution in methanol, to obtain 0.89 g (Yield:46%) of the captioned compound as a light yellow oily product.

IR(neat, cm⁻¹): 3300, 3150, 3050, 2950, 1620, 1260, 1160, 1040, 850,695, 520.

NMR(CDCl₃, ppm): 1.2-1.9 (6H, m), 2.2-2.7 (4H, m), 2.9 (3H, s), 3.5 (2H,s), 3.8-4.2 (2H, m), 4.4-4.7 (2H, m), 5.5-5.8 (2H, m), 6.5-7.3 (4H, m).

EXAMPLE 17 Preparation of3-amino-4-[4-<3-(1-pyrrolidinomethyl)phenoxy>-cis-2-butenylamino]-1,2,5-thiadiazol-1-oxide##STR40##

Yield: 81.0%

Melting Point: 76° to 84° C.

IR(KBr, cm⁻¹): 3250, 2800, 1670, 1580, 1490, 1450, 1280, 1050, 880, 810,700, 630.

NMR(CDCl₃, ppm): 1.4-2.0 (4H, m), 2.2-2.7 (4H, m), 3.3-3.7 (2H, s),3.7-4.3 (2H, m), 4.4-4.8 (2H, m), 5.4-5.9 (2H, m), 6.5-7.4 (6H, m, 2HDisappeaved by D₂ O treatment).

EXAMPLE 18 Preparation of3-methylamino-4-[4-<3-(1-pyrrolidinomethyl)phenoxy>-cis-2-butenylamino]-1,2,5-thiadiazol-1-oxide##STR41##

The resultant product was a light yellow oily substance, and the yieldwas 70.5%.

IR (nest, cm⁻¹): 3400, 2950, 2500, 1600, 1490, 1450, 1370, 1330, 1250,1170, 1040, 900, 840, 780, 695, 625, 520.

NMR (DMSO-d₆ /CDCl₃, ppm): 1.7-2.0 (4H, m), 2.7-3.2 (4H, m), 4.0 (2H,s), 4.2 (3H, s), 4.4-4.7 (2H, m), 5.5-5.7 (2H, m), 6.7-7.4 (4H, m).

EXAMPLE 19 preparation of3-isopropylamino-4-[4-<3-(1-piperidinomethyl)phenoxy>-cis-2-butenylamino]-1,2,5-thiadiazol-1-oxide##STR42##

Yield: 67.3%

Melting Point: 105° to 110° C.

IR(KBr, cm⁻¹): 3300, 2950, 1610, 1570, 1490, 1450, 1370, 1340, 1260,1150, 1030, 910, 875, 690, 630, 530.

NMR(CDCl₃, ppm): 0.9-1.5 (6H, d), 1.3-1.8 (6H, m), 2.15-2.6 (4H, m),3.45 (2H, s), 3.75-4.35 (2H, m), 4.45-4.75 (2H, m), 5.55-5.95 (2H, m),6.45-7.75 (4H, m), 7.65-8.45 (1H, bro, Vanished by the treatment with D₂O).

EXAMPLE 20 Preparation of3-n-propylamino-4-[4-<3-(1-piperidinomethyl)phenoxy>-cis-2-butenylamino]-1,2,5-thiadiazol-1-oxide##STR43##

The resultant product was a light yellow oily substance, and the yieldwas 85.3%.

IR(neat, cm⁻¹): 3300, 2950, 1610, 1580, 1490, 1450, 1345, 1260, 1160,1040, 950, 840, 775, 695.

NMR(CDCl₃, ppm): 0.7-1.1 (3H, t), 1.2-1.8 (6H, m), 2.15-2.6 (4H, m),2.8-3.5 (4H, m), 3.45 (2H, s), 3.8-4.2 (2H, m), 4.4-4.7(2H, m),5.5-5.8(2H, m), 6.5-7.1(4H, m).

EXAMPLE 21 Preparation of3-<4-(3-dimethylaminomethylphenoxy)-cis-2-butenylamino>-4-amino-1,2,5-thiadiazol-1-oxide##STR44##

Yield: 43.5%

Melting Point: 78° to 80° C.

IR(KBr, cm⁻¹): 3300, 2950, 1670, 1590, 1500, 1450, 1260, 1160, 1030,880, 810, 700, 630.

NMR(DMSO-d₆, ppm): 2.35 (6H, s), 3.5 (2H, s), 4.1-4.4 (2H, m), 4.6-4.9(2H, m), 5.6-6.1 (2H, m), 6.6-7.3 (4H, m), 7.7-8.1 (2H, bro. Vanished bythe treatment with D₂ O), 8.3-8.7 (1H, bro. Disappeared by D₂ Otreatment).

EXAMPLE 22 Preparation of3-<4-(3-dimethylaminomethylphenoxy)-cis-2-butenylamino>-4-methylamino-1,2,5-thiadiazol-1-oxide##STR45##

The resultant product was a light yellow oily substance, and the yieldwas 72.3%.

IR(neat, cm⁻¹): 3310, 3050, 1610, 1490, 1450, 1415, 1260, 1160, 1040,840, 695, 630, 580, 520.

NMR(CDCl₃, ppm): 2.45 (6H, s), 3.1 (3H, 8), 3.65 (2H, s), 4.1-4.3 (2H,m), 4.6-4.9 (2H, m), 5.7-6.1 (2H, m), 6.7-7.4 (4H, m).

EXAMPLE 23 Preparation of3-amino-4-[4-<3-(1-piperidinomethyl)phenoxy>-cis-2-butenylamino]-1,2,5-thiadiazol

Step (A): Preparation ofN-[4-<3-(1-piperidinomethyl)phenoxy>-cis-2-butenyl]-ethanediimidamidetrihydrochloride;

4.2 g (0.0112 mol) of3-amino-4-[4-<3-(1-piperidinomethyl)phenoxy>-cis-2-butenylamino]-1,2,5-thiadiazol-1-oxide obtained in Example 15 was dissolved in 100 ml of methanol, addedwith 7.99 ml of conc. hydrochloric acid while cooling, and then agitatedat room temperature for 4 hours.

The reaction mixture was concentrated under reduced pressure after thecompletion of the reaction, and the residue was added with 10 ml of2-propanol followed by concentration under reduced pressure. Theaforementioned operations were repeated for additional two cycles toremove water by azeotropic boiling. The crystalline residue was addedwith 3 ml of absolute alcohol, and the admixture was ground intimately,cooled and then filtered to obtain 3.3 g of the captioned compound in acolorless powdered crystal form (Yield: 71.8%). The melting point of theproduct compound was 180° to 188° C., at which the product wasdecomposed.

IR(KBr, cm⁻¹): 2950, 1700, 1500, 1455, 1270, 1170, 1050, 980, 770, 700.

NMR(DMSO-d₆ ppm): 1.2-2.2(6H, m), 2.2-3.8(4H, m), 4.2(2H, s),4.5-4.9(2H, m), 5.5-6.0(2H, m), 6.7-7.5(4H, m), 9.5-11.00(4H, b).

Step (B): Preparation of3-amino-4-[4-<3-(1-piperidinomethyl)phenoxy>-cis-2-butenylamino]-1,2,5-thiadiazol;

A mixture of 1.0 g (0.00228 mol) ofN-[4-<3-(1-piperidinomethyl)phenoxy>-cis-2-butenyl]-ethanediimidamidetrihydrochloride prepared by the step (A) of this Example, 10 ml of CH₂Cl₂ and 0.69 g (0.00684 mol) of triethylamine was added with 2.216 g(0.0068 mol) of N, N'-thiobisphthalimide (prepared by the processreported by M. V. Kalnins, Canadian Journal of Chem., 44, 2111 (1966))little by little at room temperature under agitation, followed byadditional agitation at room temperature for 2 hours.

After the completion of the reaction, 10 ml of a 20% aquesous KOHsolution was added thereto and shaked. Then, the organic phase wasseparated and dried with MgSO₄. The solvents were distilled off underreduced pressure, and the residue was purified by passing through asilica gel column chromatogram, followed by elution with a mixedsolution of ethyl acetate ethanol/ammonia=6/1/1, whereby 0.35 g of thecaptioned compound was obtained as a light yellow oily product (Yield:40.0%)

IR(neat, cm⁻¹): 3400, 2950, 1640, 1570, 1450, 1250, 1120, 1040, 990,775, 700, 620.

NMR(CDCl₃, ppm): 1.15-1.85(6H, m), 2.1-2.6(4H, m), 3.37(2H, s),3.7-4.3(2H, m), 4.3-4.65(2H, d), 4.5-5.2(2H, b, Disappeared by D₂ Otreatment), 5.4-6.0 (2H, m), 6.5-7.3(4H, m).

EXAMPLE 24 PREPARATION OF3-[4-<3-(1-piperidinomethyl)phenoxy>-trans-2-butenylamino]-4-amino-1,2,5-thiadiazol##STR46##

The oily product was obtained at an yield of 27.5%.

IR(neat, cm⁻¹): 3400, 3350, 3210, 2950, 1660, 1490, 1450, 1255, 1160,1040, 850, 770, 690.

NMR(CDCl₃, ppm): 1.2-1.7(6H, m), 2.1-2.6(4H, m), 3.25(2H, s),3.6-4.0(2H, m), 4.2-4.6(2H, m), 5.5-6.0(2H, m), 6.5-7.3(4H, m).

EXAMPLE 25 Preparation of2-amino-5-[4-<3-(1-piperidinomethyl)phenoxy>-trans-2-butenylamino]-1,3,4-thiadiazol

0.65 g (0.0025 mol) of4-<3-(1-piperidinomethyl)phenoxy>-trans-2-butenylamine and 0.37 g(0.0025 mol) of 2-amino-5-bromo-1,3,4-thiadiazol (prepared by theprocess reported by Pathgeb, Paul et al, German Offenlegeschrift No.2,156,672) were dissolved in 10 ml of ethanol and sealed in aBonbenrohr, and then the content in the Bonbenrohr was stirred at atemperature of from 100° to 110° C. for 8 hours.

After the completion of the reaction, the solvent was distilled offunder reduced pressure, and the residue was purified by passing the samethrough a silica gel column chromatogram, followed by elution with amixed solution of ethyl acetate/methanol=4/1, whereby 0.55 g of thecaptioned compound was obtained in a colorless crystal form (Yield:64.0%). The melting point of the product crystal was 133° to 134° C. (inisopropanol).

IR(KBr, cm⁻¹): 3300, 2950, 1620, 1584, 1520, 1455, 1340, 1300, 1260,1160, 1140, 1035, 960, 875, 770, 695.

NMR(CDCl₃, ppm): 1.1-1.9(6H, m), 2.1-2.7(4H, m), 3.5(2H, s),3.65-4.0(2H, m), 4.2-4.6(2H, m), 5.2-6.1(m, 4-5H, Disappeared by D₂ Otreatment).

EXAMPLE 26 Preparation of2-methylamino-5-[4-<3-(1-piperidinomethyl)-phenoxy>-trans-2-butenylamino]-1,3,4-thiadiazol

Step (A): Preparation of2-bromo-5-[4-<3-(1-piperidinomethyl)-phenoxy>-trans-2-butyenylamino]-1,3,4-thiadiazol;

0.7 g (0.002 mol) of4-<3-(1-piperidinomethyl)phenoxy>-trans-2-butenylamine was dissolved in10 ml of ethanol, and added with 0.66 g (0.0027 mol) of2,5-dibromo-1,3,4-thiadiazol (prepared by the process reported by R.Stolle and K. Fehrenbach, J. Prakt. Chem., 122, 289-318 (1927)) and theadmixture was agitated under reflux for 8 hours.

After the completion of the reaction, the solvent was distilled off andthe residue was purified by passing the same through a silica gel columnchromatogram, followed by elution with a mixed solution of ethylacetate/methanol=9/1, whereby 0.7 g of the captioned compound wasobtained in a light yellow oily product (Yield: 61.0%).

IR(neat, cm⁻¹): 3300, 2950, 1440, 1350, 1260, 1160, 1030, 770, 700.

NMR(CDCl₃, ppm): 1.3-1.8(6H, m), 2.15-2.6(4H, m), 3.4(2H, s),3.8-4.1(2H, m), 4.3-4.6(2H, m), 5.75-6.0(2H, m), 6.5-7.3(4H, m).

Step (B): Preparation of2-methylamino-5-[4-<3-(1-piperidinomethyl)-phenoxy>-trans-2-butenylamino]-1,3,4-thiadiazol

0.5 g of the brominated product obtained through the step (A) set forthhereinabove was dissolved in 10 ml of a 40% solution of methylamine inmethanol, and the solution was sealed in a Bonbenrohr and the content inthe Bohnbenrohr was stirred at 100° C. for 3 hours.

After the completion of the reaction, the solvent was distilled off andthe residue was purified by passing the same through a silica gel columnchromatogram, followed by elution with a mixed solution of ethylacetate/methanol=9/1, whereby 0.2 g of the captioned compound wasobtained in a colorless crystal form (Yield: 50%). The thus obtainedcrystal had a melting point of 87° to 92° C.

IR(KBr, cm⁻¹): 3200, 2950, 1615, 1500, 1260

NMR(CDCl₃, ppm): 1.2-1.8(6H, m), 2.15-2.6(4H, m), 3.3(3H, s), 3.4(2H,s), 3.6-4.0(2H, m), 4.2-4.5(2H, m), 4.6-5.1(1H, b, Disappeared by D₂ Otreatment), 5.65-5.9(2H, m), 6.5-7.2(4H, m).

EXAMPLE 27 Preparation of2-amino-5-[4-<3-(1-piperidinomethyl)-phenoxy>-cis-2-butenylamino]-1,3,4-thiadiazol##STR47##

An oily product was obtained at an yield of 63.7%.

IR(neat, cm⁻¹): 3270, 3170, 2950, 1580, 1510, 1440, 1340, 1250, 1160,1110, 1030, 990, 860, 770, 690.

NMR(CDCl₃, ppm): 1.2-1.9(6H, m), 2.2-2.6(4H, m), 3.4(2H, s), 3.8-4.2(2H,m), 4.4-4.8(2H, m), 5.5-6.02H, m), 5.1-5.6(2H, bro. Disappeaved by D₂ Otreatment), 6.5-7.4(5H, m, Disappeaved by D₂ O treatment).

EXAMPLE 28 Preparation of2-methylamino-5-[4-<3-(1-piperidinomethyl)-phenoxy>-cis-2-butenylamino]-1,3,4-thiadiazol##STR48##

An oily product was obtained at an yield of 72.4%

IR(neat, cm⁻¹): 3210, 2950, 1610, 1490, 1440, 1330, 1255, 1145, 1035,860, 770, 690.

NMR(CDCl₃, ppm): 1.4-1.9(6H, m), 2.3-2.7(4H, m), 3.3(3H, s), 3.5(2H, s),3.8-4.2(2H, m), 4.4-4.8(2H, m), 5.5-5.9(2H, m), 6.6-7.5(5H, m, 1HDisappeared by D₂ O treatment).

EXAMPLE 29 Preparation of2-amino-5-[4-<3-(1-pyrrolidinomethyl)-phenoxy>-cis-2-butenylamino]-1,3,4-thadiazol##STR49##

Yield: 45.8%

Melting Point: 42° to 46° C. IR(KBr, cm¹): 3250, 2950, 2700, 2450, 1600,1580, 1510, 1450, 1260, 1160, 1020, 860, 780, 700.

NMR (CDCl₃, ppm): 1.5-2.2(4H, m), 2.8-3.5(4H, m), 4.25(2H, s),3.5-4.0(2H, m), 4.4-4.8(2H, m), 4.6-5.1(2H, m, bro. Disappeared by D₂ Otreatment).

EXAMPLE 30 Preparation of2-methylamino-5-[4-<3-(1-pyrrolidinomethyl)-phenoxy>-cis-2-butenylamino]-1,3,4-thiadiazol##STR50##

Yield: 79.0%

Melting Point: 44° to 49° C.

IR(KBr, cm⁻¹): 3230, 2950, 1610, 1490, 1450, 1380, 1330, 1260, 1030,870, 780, 690.

NMR(DMSO-d₆ /CDCl₃, ppm): 1.2-1.7(4H, m), 2.0-2.6(4H, m), 3.0(3H, s),3.4(2H, s), 3.4-3.7(2H, m), 4.1-4.5(2H, m), 5.1-5.5(2H, m), 5.4-5.8(1H,bro. Disappeared by D₂ O treatment), 6.0-7.0(4H, m).

REFERENCE EXAMPLE 1 Preparation of3-amino-4[4-<3-(1-piperidinomethyl)phenoxy>-cis-2-butenylamino]-1,2,5-thiadiazol-1,1-dioxide

The captioned was prepared by repeating similar procedures as in Example15, except that 3,4-dimethoxy-1,2,5-thiadiazol-1,1-dioxide was used inlieu of 3,4-dimethoxy-1,2,5-thiadiazol-1-oxide.

IR(KBr, cm⁻¹): 3310, 2950, 1640, 1610, 1450, 1330, 1150, 870, 650, 540.

NMR(DMSO-d₆ CDCl₃, ppm): 1.0-1.7(6H, m), 2.0-2.6(4H, m), 3.35(2H, s),3.6-4.2(2H, m), 4.3-4.7(2H, m), 5.4-5.7(2H, m), 6.6-7.2(4H, m).

REFERENCE EXAMPLE 2 Preparation of3-methylamino-4-[4-<3-(1-piperidinomethyl)-phenoxy>-cis-2-butenylamino]-1,2,5-thiadiazol-1,1-dioxide

The captioned compound was prepared by repeating similar procedures asin Reference Example, 1, except that a 40% methylamine solution inmethanol was used in lieu of ammonia gas.

IR(neat, cm⁻¹): 3350, 2900, 1630, 1450, 1270, 1150, 1030, 910, 770, 640,540.

NMR(DMSO-d₆ /CDCl₃, ppm): 1.1-1.7(6H, m), 2.0-2.6(4H, m), 2.95(3H, s),3.4(2H, m), 3.9-4.3(2H, m), 4.4-4.8(2H, m), 5.5-6.0(2H, m), 6.6-7.4(4H,m).

What is claimed is:
 1. An amino alkyl phenoxy derivative having theformula: ##STR51## wherein R¹ and R² are individually hydrogen atoms orlower alkyl groups having 1 to 4 carbon atoms, or R¹ and R² form,together with a bonded nitrogen atom, a 4 to 8 member heterocyclic ringselected from the group consisting of azetidino-, pyrrolidino-,piperidino- and perhydroazepino- groups, which is unsubstituted orsubstituted by one or more hydroxyl, methoxy, ethoxy, or lower alkylgroups of 1 to 6 carbon atoms; A is a straight-chain or a branched-chainalkylene group having 1 to 4 carbon atoms; and Z is a moiety of theformula: ##STR52## wherein R¹¹ and R¹² are each hydrogen, or loweralkyl, lower alkenyl, lower alkynyl or lower alkyl groups or aheterocyclic aryl alkyl group selected from the group consisting of2-pyridinomethyl, 3-pyridinomethyl, 2-thiophenomethyl,3-thiophenomethyl, 2-furanomethyl and 3-furanomethyl; or a heterocyclicgroup formed respectively by R¹¹ and R¹² together with the nitrogen atombonded therewith selected from the group consisting of azetidino-,pyrrolidino- and piperidino- rings; or a hydrate, salt or solvatethereof.
 2. An aminoalkylphenoxy derivative of claim 1 which is selectedfrom the group consisting of2-amino-5-[4-<3-(1-piperidinomethyl)phenoxy>-trans-2-butenylamino]-1,3,4-thiadiazol,2-methylamino-5-[4-<3-(1-piperidinomethyl)-phenoxy>-trans-2-butenylamino]-1,3,4-thiadiazol,2-amino-5-[4-<3-(1-piperidinomethyl)phenoxy>-cis-2-butenylamino]-1,3,4-thiadiazol,2-methylamino-5-[4-<3-(1-piperidinomethyl)-phenoxy>-cis-2-butenylamino]-1,3,4thiadiaxol,2-amino-5-[4-<3-(1-pyrrolidinomethyl)-phenoxy>-cis-2-butenylamino]-1,3,4-thadiazoland2-methylamino-5-[4-<3-(1-pyrrolidinomethyl)-phenoxy>-cis-2-butenylamino]-1,3,4-thiadiazol.3. An amino alkyl phenoxy derivative having the formula (I) or (II):##STR53## or a hydrate, salt or solvate thereof.